Search companies

Live

PARADIGM BIOPHARMACEUTICALS LIMITED.. (ASX: PAR)

Health care · News and insights

Price unavailable

Latest PAR announcements

Paradigm Reports Phase 3 Trial Futility as Administrators Review Next Steps

2026-10-30 · Health care

PAR: $0.245 +0.00% · MC: $153M

Paradigm Biopharmaceuticals reported that its Phase 3 trial met the pre-set futility criterion, and voluntary administrators were appointed at quarter-end. Since then, a regional analysis identified encouraging pain and function findings, while independent review of the data is underway to inform assessment of the program and possible future development. The company ended the quarter with approximately A$4 million in cash; a recent court-approved extension gives administrators until January to convene a creditors’ meeting, though they anticipate acting sooner.

Updated 2026-10-30 11:14
Share
SourcesSeptember 2026 Quarterly Activities Report & Appendix 4C
Comments

Paradigm Biopharmaceuticals creditors’ meeting deadline extended to January

2026-10-28 · Health care

PAR: $0.245 +0.00% · MC: $153M

The Supreme Court of Western Australia extended the deadline for Paradigm Biopharmaceuticals’ second creditors’ meeting to 27 January 2027. The administrators say they expect to issue their report and convene the meeting in the coming weeks, but retain the option to use the extended period.

Updated 2026-10-28 16:59
Share
SourcesConvening Period Extended to 27 January 2027
Comments